Class / Patent application number | Description | Number of patent applications / Date published |
530389800 | Binds drug, hapten, hapten-carrier complex, or specifically-identified chemical structure (e.g., theophylline, digoxin, etc.) | 21 |
20090209733 | THERAPEUTIC AGENT FOR RHEUMATOID ARTHRITIS - A therapeutic agent for rheumatoid arthritis, particularly a therapeutic agent for ameliorating an inflammatory symptom or bone deformity in rheumatoid arthritis, which comprises an antibody that binds to a hepatocyte growth factor receptor as an active ingredient. | 08-20-2009 |
20110060131 | MONOSPECIFIC ANTIBODY AND METHOD OF PRODUCTION USING AS ANTIGEN AN ISOFORM OF THE HUMAN FAD SYNTHETASE - Antibody and method of production of antibodies obtained using as antigen an isoform of the human FAD synthetase, obtained by means of technology of recombinant DNA cloned and over-expressed in microorganisms cultures in particular a colony of | 03-10-2011 |
20110130549 | Method for the treatment of amyloidoses - The present invention relates to a method for the treatment of an amyloidosis such as Alzheimer's disease in a subject in need thereof, characterized in that it comprises administering an inhibitor of the interaction between Aβ globulomer and the P/Q type voltage-gated presynaptic calcium channel to said subject. | 06-02-2011 |
20110230649 | Compositions and Methods for Redox Modulated Proteins - Disclosed embodiments relate to antibodies that recognize redox modulated proteins such as glutathionylated actin. Embodiments relate to a reagent for the immunoassay of glutathionylated actin. Disclosed embodiments also relate to diagnosis of and therapies for the treatment of diseases related to impaired deglutathionylation of peptides. Additionally, disclosed embodiments relate to pharmaceutical compositions containing antibodies which recognize redox modulated proteins and kits for the detection or treatment of diseases related to redox modulated proteins which include antibodies that recognize redox modulated proteins. | 09-22-2011 |
20120077964 | ANTAGONISTS OF PCSK9 - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 03-29-2012 |
20120142903 | Methods For Detecting And Analyzing N-Glycolylneuraminic Acid (NEU5GC) In Biological Materials - The present application is in the field of sialic acid chemistry, metabolism and antigenicity. More particularly, the present invention relates to the detection and analysis of the non-human sialic acid, N-glycolylneuraminic acid (Neu5Gc) in biological materials, such as food and clinical specimens. Such detection and analysis is facilitated by the use of Neu5Gc specific antibodies. The present invention also relates to the detection of antiNeu5Gc antibodies in clinical samples, as well as the production of anti-Neu5Gc specific antibodies. | 06-07-2012 |
20130066053 | Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits. | 03-14-2013 |
20130072665 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 03-21-2013 |
20130245237 | Analysis of Ubiquitinated Polypeptides - The invention relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis | 09-19-2013 |
20130267689 | ANTIBODIES AND DIAGNOSTICS - Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided. | 10-10-2013 |
20130303735 | METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT - A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. | 11-14-2013 |
20130310545 | Inhibitors of Branched-Chain-Aminotransferase-1 (BCAT1) for the Treatment of Brain Tumors - Described is a compound capable of reducing or inhibiting (a) the biological activity of branched-chain-aminotranferase-1 (BCAT1) or (b) the expression of the gene encoding BCAT1 for use in a method of treating a neoplasia. A preferred compound is 1-(aminomethyl) cyclohexaneacetic acid (gabapentin). | 11-21-2013 |
20130317204 | Purification of Proteins - The present invention relates to a selectively soluble polymer capable of binding to a desired molecules in an unclarified mixture containing various biological materials and the methods of using such a polymer to purify a molecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and/or salt concentration and is rendered insoluble and precipitates out of solution upon a change in the process conditions. The polymer is capable of binding to the desired molecule (protein, polypeptide, etc) and remains capable of binding to that molecule even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered such as by elution and further processed. | 11-28-2013 |
20140018523 | PROTEIN PURIFICATION - A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants. | 01-16-2014 |
20140039165 | ANTI-NR10 ANTIBODY AND USE THEREOF - The present inventors successfully obtained anti-NR | 02-06-2014 |
20140171624 | MODULATORS OF ADP-DEPENDENT GLUCOKINASE (ADPGK) AND GLYCEROL-3-PHOSPHATE DEHYDROGENASE (GPD2) FOR THERAPY - Described are compounds capable of modulating (a) the biological activity of ADP-dependent glucokinase (ADPGK) and/or glycerol-3-phosphate dehydrogenase (GPD2) or (b) the expression of the gene encoding ADPGK or GPD2 for use in treating a disease (a) associated with aberrant cell proliferation, e.g., a neoplasm, or (b) of the immune system, e.g., an autoimmune disease. | 06-19-2014 |
20140179905 | METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN - Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided. | 06-26-2014 |
20140221626 | COMPOSITIONS AND METHODS FOR DETECTION OF METHADONE METABOLITE - Methods and reagents are disclosed for conducting assays for EDDP. The reagents include a moiety selected from the group consisting of poly(amino acid) label moieties, non-poly(amino acid) label moieties, poly(amino acid) immunogenic carriers, non-poly(amino acid) immunogenic carriers, non-label poly(amino acid) moieties, and non-immunogenic carrier poly(amino acid) moieties linked to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine at the 3-position of one of the phenyl rings. Antibodies produced from immunogenic EDDP conjugates and labeled EDDP conjugates are employed in assays for determining the presence and/or amount of EDDP in samples suspected of containing EDDP. | 08-07-2014 |
20140275495 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease. | 09-18-2014 |
20150065693 | COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF VASCULAR OR CARDIAC VALVULAR CALCIFICATION COMPRISING DIPEPTIDYL PEPTIDASE-4 INHIBITOR - There is provided a composition for prophylaxis or treatment of vascular or valvular calcification including a dipeptidylpeptidase-4 (DPP-4) inhibitor. The DPP-4 according to one exemplary embodiment of the present disclosure is expressed at an increased level when blood vessels and valves are calcified, and the calcification decreases remarkably upon administration of the DPP-4 inhibitor. Therefore, the DPP-4 inhibitor can be useful in treatment or prophylaxis of blood vessels or valves. | 03-05-2015 |
20160200834 | Antibody and Recombinant Derivative for the Detection of Trinitrotoluene | 07-14-2016 |